Early-life Factors and Cancer Development Later in Life (R21 - Clinical Trial Not Allowed) | PA 18 532

Opportunity Information: Apply for PA 18 532

The National Institutes of Health (NIH) funding opportunity titled "Early-life Factors and Cancer Development Later in Life" (PA-18-532) is an R21 exploratory/developmental research grant aimed at building new knowledge about how events and exposures earlier in life shape cancer risk decades later. The FOA is centered on the idea that cancer susceptibility may be influenced long before adulthood, including during preconception and pregnancy (maternal and paternal factors), in utero development, birth and infancy, puberty, adolescence, and the young adult years. While evidence in this area is growing, it is still limited, and NIH is using this announcement to encourage innovative, early-stage projects that can open up new lines of investigation. Clinical trials are not allowed under this specific announcement.

The research focus is threefold. First, NIH is looking for studies that identify which early-life factors are associated with cancer development later in life. These factors can include a wide range of exposures and conditions such as parental health and behaviors, prenatal and perinatal conditions, early nutrition, growth patterns, environmental and chemical exposures, infections and immune-related events, stress and psychosocial factors, endocrine and metabolic influences, and developmental timing issues like pubertal onset. Second, the FOA emphasizes understanding mechanisms, meaning applicants are expected to go beyond simple associations and explore how early-life factors might influence biological processes tied to carcinogenesis. This can involve investigating pathways such as inflammation, immune development, hormonal signaling, epigenetic programming, DNA damage and repair capacity, microbiome development, metabolic reprogramming, or tissue and organ development that could create long-term vulnerability or resilience to malignancy. Third, the FOA prioritizes the development or evaluation of predictive markers that reflect early biological changes linked to later cancer risk. The practical motivation is clear: because many cancers take decades to appear, validated early markers of malignancy or premalignant states could let researchers and public health programs assess risk and intervention effects without waiting a lifetime for cancer outcomes to occur.

A major theme of the opportunity is prevention-oriented impact. By clarifying how early developmental windows contribute to the origins of cancer, the research supported through this FOA is intended to lay groundwork for interventions during pregnancy or early life that could meaningfully reduce cancer burden across the lifespan. This might include strategies that reduce harmful exposures, improve maternal and child health conditions, or identify high-risk individuals earlier through biomarker-informed screening or monitoring approaches. The R21 mechanism is especially suited to high-impact pilot work, proof-of-concept studies, novel measurement strategies, and exploratory analyses that can later be scaled into larger projects.

From an administrative standpoint, this is a discretionary NIH grant under CFDA 93.393, using the R21 funding instrument. The listed award ceiling is $200,000 (as provided in the source data). The original closing date shown is January 7, 2021, and the FOA was created on December 20, 2017. Even when specific submission dates pass, FOAs sometimes have reissues or related active announcements, so applicants typically verify current availability and deadlines through NIH and Grants.gov postings.

Eligibility is broad and includes many types of organizations. Eligible applicants include state, county, city or township, and special district governments; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, U.S. territories or possessions, eligible federal agencies, regional organizations, and non-U.S. entities (foreign organizations). This wide eligibility reflects NIH interest in drawing on diverse populations, settings, and expertise, which is often essential for studying early-life exposures and life-course cancer risk across different communities and environments.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Early-life Factors and Cancer Development Later in Life (R21 - Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393.
• This funding opportunity was created on 2017-12-20.
• Applicants must submit their applications by 2021-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $200,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 18 532

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: